Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 dose-ranging monotherapy study versus placebo with open-label metformin in type 2 diabetes
2008-000640-14Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change in HbA1c from baseline after 12 weeks of treatment. Started Aug 2008; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-000640-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000640-14.